KPV

Origin and Structure

KPV is a tripeptide with the sequence Lys-Pro-Val, corresponding to the C-terminal three residues of α-melanocyte-stimulating hormone (α-MSH). α-MSH is a 13-residue pro-opiomelanocortin-derived peptide best known for its role in pigmentation, appetite regulation, and anti-inflammatory signaling at the melanocortin receptors. KPV was identified in the 1990s and early 2000s when several groups — notably those investigating the anti-inflammatory activity of α-MSH — demonstrated that the C-terminal tripeptide retained most of the parent peptide's inflammation-suppressing activity while shedding its pigmentation and neuroendocrine effects.

That dissociation is the central point about KPV: it is α-MSH minus the melanocortin-receptor-mediated "hormone" activity. The tripeptide does not significantly engage MC1R, MC3R, MC4R, or MC5R at physiological concentrations, so it does not drive pigmentation, appetite changes, or the sexual-arousal effects associated with MC4R agonists like PT-141.

Mechanism of Action

KPV's anti-inflammatory effects appear to be PepT1-mediated rather than melanocortin-receptor-mediated. PepT1 is a proton-coupled oligopeptide transporter expressed on intestinal epithelial cells and — importantly — upregulated on immune cells and colonic epithelium during intestinal inflammation. This creates a mechanism in which KPV is preferentially taken up into inflamed tissue. Once inside the cell, KPV:

• Inhibits NF-κB activation, blocking transcription of downstream pro-inflammatory cytokines.
• Suppresses MAP-kinase inflammatory signaling, including p38 and JNK pathways.
• Reduces pro-inflammatory cytokine secretion (TNF-α, IL-6, IL-8) from macrophages and epithelial cells.

Preclinical Evidence

The strongest KPV data is in models of inflammatory bowel disease. Orally and rectally administered KPV reduces disease severity in DSS- and TNBS-induced colitis in mice, with improvements in histological scores, myeloperoxidase activity, and weight preservation. A notable 2008 paper in Gastroenterology established the PepT1-mediated uptake mechanism and made the case for KPV as a targeted anti-inflammatory for IBD specifically. More recent work has focused on nanoparticle delivery systems that concentrate KPV at colonic inflammation sites.

Skin inflammation is the second major preclinical cluster. Topical KPV attenuates contact hypersensitivity and reduces inflammation in atopic-dermatitis-like models, though the topical bioavailability of a hydrophilic tripeptide is limited without formulation help.

Human Clinical Data

Published, peer-reviewed human trials of KPV are sparse. Small case series and open-label observational reports exist for inflammatory bowel disease and skin inflammation, but no adequately powered placebo-controlled Phase 2 or Phase 3 data has been published as of 2026. The evidence base is therefore strongly preclinical, with human use running ahead of the formal trial record in the wellness and compounding space.

Practical Considerations

Community protocols typically use KPV at 200–1000 mcg per day, most commonly via subcutaneous injection, oral capsule, or compounded topical formulation. Oral use is biologically plausible given PepT1-mediated uptake — and unlike most peptides, KPV has at least some theoretical rationale for oral activity at the site of action (the GI tract). Injection protocols target systemic anti-inflammatory effect, typically stacked with BPC-157 in community gut-healing regimens, though no head-to-head or combination clinical trials support this pairing.

Safety and Regulatory Status

KPV's preclinical safety profile is clean — no significant toxicity at doses many orders of magnitude above the effective anti-inflammatory range, and no melanocortin-receptor side effects because the relevant binding motif is absent. Human adverse events reported in anecdotal and case-series contexts are mild: occasional injection-site reactions, transient GI upset with oral dosing. Long-term safety is unknown.

KPV is not FDA-approved for any indication. It is not on the WADA prohibited list. In the United States, it has generally been available through compounding pharmacies, though the regulatory picture around peptide compounding has tightened since the FDA's 2023–2025 actions on the Category 2 bulk substance list.

The Bottom Line

KPV occupies an unusually well-defined niche for a research-market peptide: a real mechanistic story (PepT1-mediated anti-inflammatory uptake), reproducible preclinical efficacy in colitis, a clean safety signature, and meaningful drug-development interest. What it lacks is the pivotal human clinical data that would move it from "promising" to "validated." For IBD-adjacent use cases, KPV is one of the more mechanistically defensible peptides on this library — with the important caveat that "defensible" is not the same as "proven."